Search research articles
Contact Us
Filters
Showing results (121-130 of 142) with videos related to
Page
of 15
Sort By:
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Cancers
|
July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
Romain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Benoit You, Patrick Robelin, Michel Tod, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 31, 2024
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, Alice Durand, Marion Chevrier, et al.
Biomarker Research
|
July 2, 2025
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Benoit You, Sebastien Couraud, Philippe Ceruse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
Marie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 142) with videos related to
Sort By:
Page
of 15
JCO Oncology Practice
|
November 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer
Claudia Marchetti, Gwenael Ferron, Olivier Colomban, et al.
Cancers
|
July 14, 2023
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
Olivier Trédan, Maud Toulmonde, Christophe Le Tourneau, et al.
Gynecologic Oncology
|
December 13, 2024
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial
Henri Azaïs, Camille Brochard, Valérie Taly, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 28, 2019
Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
Romain Varnier, Olivia Le Saux, Sylvie Chabaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 27, 2020
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Benoit You, Patrick Robelin, Michel Tod, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 31, 2024
Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas
Ondine Becker, Alice Durand, Marion Chevrier, et al.
Biomarker Research
|
July 2, 2025
Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study
Benoit You, Sebastien Couraud, Philippe Ceruse, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2022
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
Marie Véron, Sylvie Chevret, Jean-Jacques Grob, et al.
JCO Precision Oncology
|
January 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial
Félix Blanc-Durand, Benoit You, Yahia Adnani, et al.
Page
of 15